• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 9, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Gut Microbes Drive Methamphetamine Liver Damage Through PPARα/NF-κB Pathway

by
October 30, 2026
in Biology
Reading Time: 2 mins read
0
Gut Microbes Drive Methamphetamine Liver Damage Through PPARα/NF-κB Pathway

Gut Microbes Drive Methamphetamine Liver Damage Through PPARα/NF-κB Pathway

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new mouse study published in Cell Biology and Toxicology reports that the gut microbiota acts as a critical mediator of methamphetamine-induced hepatotoxicity, linking intestinal microbial disruption to cholestatic liver injury through the PPARα/NF-κB signaling axis.

The research team, led by Li-Jian Chen and Qi Wang, exposed mice to methamphetamine (METH) and tracked changes in both the gut microbial community and liver health. METH exposure significantly disrupted the composition of the gut microbiome, a disturbance captured by an elevated microbial dysbiosis index (MDI) and marked by the opportunistic expansion of bacteria from the Lactobacillaceae family.

That microbial shift did not stay confined to the gut.

The mechanistic core of the study lies in two transcriptional regulators. METH exposure suppressed hepatic PPARα while simultaneously activating the NF-κB pathway, evidenced by increased NF-κB phosphorylation. This combination removed a brake on inflammatory signaling in the liver at the same time that gut-derived LPS was arriving to fuel it.

To test whether the microbiome was genuinely causal rather than a bystander, the researchers ran two complementary experiments. Pretreating mice with broad-spectrum antibiotics, which deplete the gut microbiota, attenuated both hepatic damage and inflammatory signaling after METH exposure. Conversely, fecal microbiota transplantation (FMT) from METH-treated donors into naive, untreated recipients recapitulated the liver injury phenotype, confirming that the transplanted dysbiotic community was sufficient to transmit the damage.

The team also explored potential interventions. Transplanting fecal material from healthy donors restored a more balanced microbial composition, and pharmacological activation of PPARα with the agonist WY14643 effectively restored PPARα expression, suppressed NF-κB activation, and alleviated liver injury. Both healthy FMT and PPARα agonism therefore emerged as preventive strategies in the mouse model.

Together, the findings establish a gut microbiota–PPARα/NF-κB axis as a central driver of METH-induced hepatotoxicity. The authors suggest that preemptive microbiota modulation could be a promising intervention strategy against METH-associated complications, though the work so far is confined to animal models and pretreatment paradigms rather than established human therapy.

Several caveats frame the results. The study was conducted in mice, and the published version is an early-release, peer-reviewed accepted manuscript that remains subject to further editorial edits before the final Version of Record. Whether antibiotic pretreatment, fecal transplantation, or PPARα agonists could safely prevent liver injury in people who use methamphetamine remains untested, and translating microbiota-targeted interventions from rodents to humans carries well-known uncertainties.

Subject of Research: Gut microbiota mediation of methamphetamine-induced liver injury via the PPARα/NF-κB pathway in mice

Article Title: The gut microbiota mediates METH-induced hepatotoxicity via the PPARα/NF-κB pathway

Article References: Chen, L.-J., Zhao, W., Chen, Z.-J., Liu, J.-F., Wei, Q.-J., Zhang, K.-K., Tao, S.-H., & Wang, Q. (2026). The gut microbiota mediates METH-induced hepatotoxicity via the PPARα/NF-κB pathway. Cell Biology and Toxicology. https://doi.org/10.1007/s10565-026-10281-1

Image Credits: AI Generated

DOI: 10.1007/s10565-026-10281-1

Keywords: methamphetamine, gut microbiota, hepatotoxicity, PPARα, NF-κB, gut-liver axis, LPS translocation, fecal microbiota transplantation, cholestasis, intestinal permeability, WY14643, mouse study

News Source: Morgan Morrow. (October 30, 2026). Gut Microbes Drive Methamphetamine Liver Damage Through PPARα/NF-κB Pathway. Scienmag.

Tags: cholestasisFecal microbiota transplantationgut microbiotagut-liver axishepatotoxicityintestinal permeabilityLPS translocationmethamphetaminemouse studyNF-κBPPARαWY14643
Share12Tweet7Share2ShareShareShare1

Related Posts

Single Mutation Creates Highly Specific Maltose Biosensor

Single Mutation Creates Highly Specific Maltose Biosensor

November 9, 2026
Review Explores Immune and Metabolic Interactions in Intervertebral Disc Degeneration

Review Explores Immune and Metabolic Interactions in Intervertebral Disc Degeneration

November 9, 2026

Metagenomics reveals metabolic diversity in Lucky Strike iron mats

November 9, 2026

Review Details Brain Organoid Progress in Disease Modeling and Key Challenges

November 9, 2026

POPULAR NEWS

  • Ulinastatin Shortens ICU Stays in Post-Traumatic Sepsis Trial

    Ulinastatin Shortens ICU Stays in Post-Traumatic Sepsis Trial

    29 shares
    Share 12 Tweet 7
  • Simulation Study Reveals Bias in Self-Controlled Drug Safety Designs

    29 shares
    Share 12 Tweet 7
  • Metabolic Enzyme and Protein Lactylation Markers Signal Laryngeal Cancer Progression

    29 shares
    Share 12 Tweet 7
  • Marine Compounds Identified as Potential GLP-1 Receptor Agonists

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

AI Framework Detects Hidden Grouting Defects and Maps 3D Porosity in Prefabricated Building Sleeves

Somali children with severe neck infections show vacuum therapy linked to deeper disease

Single Mutation Creates Highly Specific Maltose Biosensor

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.